...
首页> 外文期刊>Antioxidants and redox signalling >Epigenetic Histone Modifications Involved in Profibrotic Gene Regulation by 12/15-Lipoxygenase and Its Oxidized Lipid Products in Diabetic Nephropathy
【24h】

Epigenetic Histone Modifications Involved in Profibrotic Gene Regulation by 12/15-Lipoxygenase and Its Oxidized Lipid Products in Diabetic Nephropathy

机译:糖尿病肾病中涉及通过12 / 15-Lipoxygenase及其氧化脂质产物调节proprobrotic基因的表观遗传组蛋白修饰。

获取原文
获取原文并翻译 | 示例

摘要

Aims: Epigenetic mechanisms, including histone post-translational modifications and DNA methylation, are implicated in the pathogenesis of diabetic nephropathy (DN), but the mediators are not well known. Moreover, although dyslipidemia contributes to DN, epigenetic changes triggered by lipids are unclear. In diabetes, increased expression of 12/15-lipoxygenase (12/15-LO) enhances oxidized lipids such as 12(S)-hydroxyeicosatetraenoic acid [12(S)-HETE], which promote oxidant stress, glomerular and mesangial cell (MC) dysfunction, and fibrosis, and mediate the actions of profibrotic growth factors. We hypothesized that 12/15-LO and its oxidized lipid products can regulate epigenetic mechanisms mediating profibrotic gene expression related to DN. Results: 12(S)-HETE increased profibrotic gene expression and enrichment of permissive histone lysine modifications at their promoters in MCs. 12(S)-HETE also increased protein levels of SET7, a histone H3 lysine 4 methyltransferase, and promoted its nuclear translocation and enrichment at profibrotic gene promoters. Furthermore, SET7 (Setd7) gene silencing inhibited 12(S)-HETE-induced profibrotic gene expression. 12/15-LO (Alox15) gene silencing or genetic knockout inhibited transforming growth factor-beta 1 (TGF-beta 1)-induced expression of Setd7 and profibrotic genes and histone modifications in MCs. Furthermore, 12/15-LO knockout in mice ameliorated key features of DN and abrogated increases in renal SET7 and profibrotic genes. Additionally, 12/15-LO siRNAs in vivo blocked increases in renal SET7 and profibrotic genes in diabetic mice. Innovation and Conclusion: These novel results demonstrate for the first time that 12/15-LO-derived oxidized lipids regulate histone modifications associated with profibrotic gene expression in MCs, and 12/15-LO can mediate similar actions of TGF-beta 1 and diabetes. Targeting 12/15-LO might be a useful strategy to inhibit key epigenetic mechanisms involved in DN. Antioxid. Redox Signal. 24, 361-375.
机译:目的:表观遗传机制,包括组蛋白翻译后修饰和DNA甲基化,与糖尿病性肾病(DN)的发病机制有关,但其介体并不为人所知。此外,尽管血脂异常会导致DN,但尚不清楚由脂质引起的表观遗传变化。在糖尿病中,增加12 / 15-脂氧合酶(12 / 15-LO)的表达会增强氧化脂质,例如12(S)-羟基二十碳四烯酸[12(S)-HETE],从而促进氧化应激,肾小球和系膜细胞(MC )功能障碍和纤维化,并介导纤维化生长因子的作用。我们假设12 / 15-LO及其氧化的脂质产物可以调节表观遗传机制,介导与DN相关的纤维化基因表达。结果:12(S)-HETE增加了促纤维化基因的表达,并在MCs的启动子上富集了允许的组蛋白赖氨酸修饰。 12(S)-HETE还增加了SET7(组蛋白H3赖氨酸4甲基转移酶)的蛋白水平,并促进了其在纤维蛋白原基因启动子上的核转运和富集。此外,SET7(Setd7)基因沉默抑制12(S)-HETE诱导的profibrotic基因表达。 12 / 15-LO(Alox15)基因沉默或基因敲除抑制了转化生长因子-beta 1(TGF-beta 1)诱导的Setd7和原纤维化基因的表达以及MC中的组蛋白修饰。此外,小鼠的12 / 15-LO敲除改善了DN的关键特征,并废除了肾脏SET7和纤维化基因的增加。此外,体内12 / 15-LO siRNA阻断了糖尿病小鼠肾脏SET7和纤维化基因的增加。创新与结论:这些新颖的结果首次证明12 / 15-LO衍生的氧化脂质调节与MCs中纤维蛋白原基因表达相关的组蛋白修饰,而12 / 15-LO可以介导TGF-beta 1和糖尿病的相似作用。靶向12 / 15-LO可能是抑制DN中涉及的关键表观遗传机制的有用策略。抗氧化。氧化还原信号。 24,361-375。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号